1/2]. 82 Pal J, Shrivastav A, Pathak HS, Sarkar DK. Immune reconstitution inflammatory syndrome associated with acquired immunodeficiency syndrome-related gastrointestinal limited Kaposi’s sarcoma presenting as acute intestinal obstruction: a case report. J Med Case Reports 2011; 5: 327. 83 Mosam A, Shaik F, Uldrick TS et al. A randomized
controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr 2012; 60: 150–157. 84 Laubenstein LJ, Krigel RL, Odajnyk CM et al. Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination selleck screening library of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984; 2: 1115–1120. 85 Gill PS, Akil B, Colletti P et al. Pulmonary Kaposi’s sarcoma: clinical findings and results of therapy. Am J Med 1989; 87: 57–61. 86 Gill P, Rarick M, Bernstein-Singer M et al. Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol
1990; 13: 315–319. 87 Gill PS, Bernstein-Singer M, Espina BM et al. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi’s sarcoma. AIDS 1992; 6: PD0332991 price 1477–1481. 88 Cadranel JL, Kammoun S, Chevret S et al. Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi’s sarcoma. Thorax 1994; 49: 958–960. 89 Rafiyath SM, Rasul M, Lee B et al. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 2012; 1: 10. 90 Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 2004; 5: 654. 91 Gill PS, Wernz J, Scadden DT et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s Aldol condensation sarcoma. J Clin Oncol 1996; 14: 2353–2364. 92 Northfelt DW, Dezube BJ, Thommes JA
et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445–2451. 93 Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16: 683–691. 94 Cooley T, Henry D, Tonda M et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Oncologist 2007; 12: 114–123. 95 Lichterfeld M, Qurishi N, Hoffmann C et al. Treatment of HIV-1-associated Kaposi’s sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection 2005; 33: 140–147.